Triggers a tan. FDA-approved as Scenesse for a rare condition where sunlight is painful. More selective and safer than MT-2.
Research referenceCommunity compiled
i
Research & reference information
This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.
Overview
Triggers a tan.
FDA-approved as Scenesse for a rare condition where sunlight is painful.
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Calculated concentration—Enter both values above.
Optional conversion
Enter a target amount you already have and select the syringe capacity.
Calculated draw—Enter concentration inputs and a target amount.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
Phase
Frequency
Amount
Notes
Loading (Weeks
2×/week
250
Loading cadence, 500 mcg/week total. Pair with daily 15–30 min UV exposure to build baseline melanin. Slower-
1–4)
SubQ
mcg
Maintenance
1×/week
250
Maintenance cadence, 250 mcg/week total (half the loading rate). Sustains pigmentation with continued UV
(Weeks 5+)
SubQ
mcg
Off
With UV
–
As desired. MT-1 has a cleaner side-effect profile than MT-2 (no nausea, libido changes, or appetite suppression). cycle
Cycle & Timing
4 weeks loading + ongoing maintenance with seasonal UV. Cleanest results with consistent UV exposure during the loading phase.
Timing
Daily during loading, then maintenance 2–3×/week.
Evidence Context
not approved; afamelanotide is the only approved α-MSH analog. Reviews flag melanoma/mole risk.
Population Considerations
Melanocortin effects hit both sexes: skin and mole darkening (melanoma monitoring), nausea, appetite drop. Same MC1R pathway in men and women.
Handling & Stacking
Injection site
SubQ abdomen or outer thigh.
Storage
Freeze-dried: -4°F.
Reconstituted: 36–46°F.
Best used within 28 days, otherwise potency gradually fades over ~4–6 weeks (structure-based estimate, no published data).
Protect from light.
Side effects
Nausea (lower than MT-2), flushing, hyperpigmentation.
What to expect
Tan builds over 2–4 wks (melanin up within days); less nausea than MT-2. Baseline skin check first. Supply math 10mg → 1 vial (5-wk @ 250 mcg × 2/wk)
Pairs well with
Vitamin D (offsets some pigmentation cofactor demand)
Avoid
Personal or family history of melanoma. Active dysplastic naevi (mole monitoring required)
Safety & Patient Education
Contraindications
Personal or family history of melanoma Atypical mole syndrome / dysplastic nevus syndrome Active skin cancer or pre-malignant skin lesions Uncontrolled hypertension Cardiovascular disease (significant) Pregnancy and lactation
Warnings
Hyperpigmentation of all melanocytes including existing moles, mole monitoring required New mole formation Transient BP elevation (PT-141: mean ~6 mmHg systolic per FDA Vyleesi label) Nausea, especially MT-2 during loading Priapism risk in men (MT-2 specifically) Spontaneous erections (MT-2) Reduced response and tachyphylaxis with frequent use More selective for MC1R; less nausea, less libido effect, less BP impact than MT-2; same melanoma surveillance still applies
Drug interactions
PDE5 inhibitors (sildenafil, tadalafil, vardenafil): additive BP effects with PT-141; separate timing per label Antihypertensives: additive or paradoxical BP effects Vasoactive drugs in general
Labs
Dermatology mole mapping (photo-documented) at baseline + ABCDE recheck every 12 weeks on-cycle, then every 6–12 months Blood pressure log at baseline and before each dose
Stop criteria
New atypical mole or rapid change in existing mole (ABCDE criteria) Sustained BP elevation above 140/90 in previously normotensive patient Priapism (sustained erection more than 4 hours): seek emergency care Severe nausea not resolving with dose reduction
Patient education
Use sunscreen during MT-1/MT-2, extra melanin doesn’t replace UV protection Photograph moles at baseline; recheck monthly ABCDE warning signs: Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolution MT-2: erections are pharmacologic, >4 hours is a medical emergency PT-141: do not exceed 1 dose per 24 hours
Standard Labs sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration.
